DAX23.955 -1,6%Est505.808 -1,5%MSCI World4.343 -0,1%Top 10 Crypto10,37 +0,7%Nas26.088 -0,7%Bitcoin69.106 +0,8%Euro1,1739 ±-0,0%Öl106,4 -1,2%Gold4.700 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Münchener Rückversicherungs-Gesellschaft 843002 Siemens Energy ENER6Y Plug Power A1JA81 SAP 716460 Lufthansa 823212 Micron Technology 869020 Infineon 623100 Intel 855681 Bayer BAY001 Deutsche Telekom 555750 AMD (Advanced Micro Devices) 863186 Allianz 840400 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen im Plus -- VW, Mercedes & Co.: Autoindustrie rechnet mit größerem Stellenabbau -- EVOTEC im Fokus
Top News
Siemens-Aktie kaum verändert: Konzern bleibt leicht hinter Markterwartungen zurück Siemens-Aktie kaum verändert: Konzern bleibt leicht hinter Markterwartungen zurück
Wertpapierleihe: Der unsichtbare Rendite-Turbo im Portfolio von ETF-Investoren Wertpapierleihe: Der unsichtbare Rendite-Turbo im Portfolio von ETF-Investoren
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Biomarin Pharmaceutical Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
45,04 EUR +0,06 EUR +0,13 %
STU
52,86 USD +0,28 USD +0,53 %
BTT
finanzen.net zero
Biomarin Pharmaceutical jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.8,66 Mrd. EUR

KGV32,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN924801

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09061G1013

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBMRN

Biomarin Pharmaceutical Aktien News

DatumMeistgelesen
PR NewswireBioMarin Appoints Arpit Davé Chief Digital and Information Officer
PR NewswireVeeva und BioMarin schließen langfristige strategische Partnerschaft
PR NewswireBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
Wer­bungBiomarin Pharmaceutical-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireVeeva and BioMarin Form Long-Term Strategic Partnership
PR NewswireVeeva and BioMarin Form Long-Term Strategic Partnership
PR NewswireBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
PR NewswireBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
PR NewswireFDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
PR NewswireBioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
PR NewswireBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
PR NewswireBioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
PR NewswireBioMarin to Participate in Upcoming Investor Conferences
PR NewswireBioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
PR NewswireBioMarin Announces Appointment of Ian T. Clark to Board of Directors
PR NewswireBioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
PR NewswireBioMarin Announces Completion of Acquisition of Inozyme
PR NewswireBioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Co...
PR NewswireBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
PR NewswireBioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
PR NewswireBioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
PR NewswireBioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
PR NewswireBioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American C...
PR NewswireBioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
PR NewswireBioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
PR NewswireBioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
PR NewswireBioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
PR NewswireBioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
PR NewswireBioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Me...
PR NewswireBioMarin to Participate in Three Upcoming Investor Conferences
PR NewswireBioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
PR NewswireBioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
PR NewswireBioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia ...
PR NewswireBioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
PR NewswireBioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
PR NewswireBioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
PR NewswireBioMarin Announces New R&D and Business Development Leadership
PR NewswireBioMarin to Host 2024 Investor Day on September 4th in New York
PR NewswireBioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
PR NewswireBioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
PR NewswireU.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Biomarin Pharmaceutical News

Biomarin Pharmaceutical News: auf dieser Seite finden Sie alle Biomarin Pharmaceutical News und Nachrichten zur Biomarin Pharmaceutical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biomarin Pharmaceutical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biomarin Pharmaceutical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.